CompletedPhase 2

Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Cells of Sclerocorneal Limbus Amplified ex Vivo

Spain10 participantsStarted 2011-11

Plain-language summary

Progenitor limbo sclerocorneal cells have properties of proliferation and differentiation to corneal and conjunctival epithelium. This cells can be isolated and ex vivo expanded using cell culture technics that could permit the biological replacement of damaged ocular surface.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

principal Inclusion Criteria: * Serious unilateral limbic insufficiency * Normal ophthalmological clinical examination in the opposite eye (biopsied eye) Exclusion Criteria: * one-eyed * serious disorders in palpebral dynamics * bilateral limbic insufficiency, immunological, systemic or local illness like toxical epidermic necrosis or pemphigoid * breastfeeding or pregnancy * positive serology of HIV, VLTH, HVC, HVB, CMV, Trypanosoma Cruzi or Treponema Pallidum

What they're measuring

Visual Acuity

Timeframe: 6 months

Trial details

NCT IDNCT01470573

SponsorFundacion Clinic per a la Recerca Biomédica

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Unilateral Limbic Insufficiency trials